Explore 3 Stock Ideas & Industry Insights Download Free Report

News

BlossomHill Therapeutics (NASDAQ:BLSM) Rockets 15%: Why Are Traders Suddenly Watching It?

● BLSM shares jumped 14.91% without a defining company announcement, reflecting a broader lift in risk appetite across biotech.

Vinay Lochav | 26 August 2026

Generate Biomedicines (NASDAQ:GENB) Breaks Out 15%: Why Is It Turning Heads?

● GENB shares climbed 15.01% amid a broad re-rating of AI-enabled and computational drug-discovery names, without a single company-specific catalyst.

Vinay Lochav | 26 August 2026

Moderna (NASDAQ:MRNA) Stock Surges 14% as Cancer-Vaccine Momentum Builds: Is Its Comeback Entering a New Phase?

● MRNA shares rose 14% as investors continued to reward the Phase 3 success of Moderna and Merck's individualized cancerVaccinein melanoma.

Vinay Lochav | 26 August 2026

Tenax Therapeutics (NASDAQ:TENX) Jumps 25%: Why Is It Back in the Spotlight?

● TENX shares jumped 25.41% in a rebound that recovers only a fraction of the value erased when the stock plunged roughly 90% on August 10 after its Phase 3 LEVEL trial missed its primary endpoint.

Vinay Lochav | 26 August 2026

Autonomix Medical (NASDAQ:AMIX) Breaks Out With a 34% Gain: Why Is It Suddenly Hot?

● AMIX shares broke out roughly 34% after an investor exercised 857,462 warrants at $5.75 per share, generating roughly $4.9 million in gross proceeds.

Vinay Lochav | 26 August 2026

Capricor Therapeutics (NASDAQ:CAPR) Explodes 22% Higher: Is It Becoming Biotech's Next Momentum Star?

● CAPR shares surged 21.91% after the FDA agreed to consider an amendedBiologicslicense application for deramiocel centered on upper-limb skeletal muscle function in Duchenne muscular dystrophy.

Vinay Lochav | 26 August 2026

AbCellera Biologics (NASDAQ:ABCL) Rips 18% Higher: Is It Becoming a Biotech Stock to Watch Again?

● Second-quarter 2026Revenuefell about 76% to roughly $4.05 million from $17.08 million a year earlier, while the net loss widened to about $55.4 million from $34.7 million.

Vinay Lochav | 26 August 2026

Anavex Life Sciences (NASDAQ:AVXL) Jumps 14%: Why Is It Suddenly Back in the Spotlight?

● AVXL shares surged 14.47% after a fiscal third-quarter update reframed the regulatory path for lead candidate blarcamesine and reassured investors about the company's financial staying power.

Vinay Lochav | 26 August 2026

Eikon Therapeutics (NASDAQ:EIKN) Rips 12% Higher: Is It Emerging as a New Biotech Momentum Name?

● EIKN shares rose 12.46% as investors positioned ahead of the ESMO Congress in late October, where seven abstracts covering the company's pipeline have been accepted.

Vinay Lochav | 26 August 2026

US Sector Momentum Analysis: Three Sectors Lead While Financials Improve

The latest US sector momentum visualization for 25 August 2026 shows three sectors in Leading, five in Improving, two in Weakening and one in Lagging. The chart indicates an active rotation environment, with momentum strengthening across several sectors while some previous leaders are losing …

Robert Luong | 25 August 2026
Support

Hi! How can we help you today?

Loading…